Publications by authors named "Wade H Aaron"
Article Synopsis
- DLL3 is found in over 70% of small cell lung cancers (SCLC), which are aggressive and have few treatment options, leading to poor patient outcomes.
- HPN328 is a new trispecific T cell-activating therapy that targets DLL3, enhances T-cell activation, and prolongs its presence in the body, showing strong tumor-killing abilities in lab and animal studies.
- Initial tests indicate HPN328 is effective and safe, with plans for a clinical trial to further evaluate its effectiveness in patients with DLL3-expressing cancers.*
Purpose: Mesothelin (MSLN) is a glycophosphatidylinositol-linked tumor antigen overexpressed in a variety of malignancies, including ovarian, pancreatic, lung, and triple-negative breast cancer. Early signs of clinical efficacy with MSLN-targeting agents have validated MSLN as a promising target for therapeutic intervention, but therapies with improved efficacy are still needed to address the significant unmet medical need posed by MSLN-expressing cancers.
Experimental Design: We designed HPN536, a 53-kDa, trispecific, T-cell-activating protein-based construct, which binds to MSLN-expressing tumor cells, CD3ε on T cells, and to serum albumin.
T cells have a unique capability to eliminate cancer cells and fight malignancies. Cancer cells have adopted multiple immune evasion mechanisms aimed at inhibiting T cells. Dramatically improved patient outcomes have been achieved with therapies genetically reprogramming T cells, blocking T-cell inhibition by cancer cells, or transiently connecting T cells with cancer cells for redirected lysis.
View Article and Find Full Text PDF